Skip to Content

Forteo (teriparatide) Disease Interactions

There are 6 disease interactions with Forteo (teriparatide):

Major

Parathyroid hormone/analogs (applies to Forteo) hyperparathyroidism

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hypercalcemia

Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.

Major

Parathyroid hormone/analogs (applies to Forteo) malignancy

Major Potential Hazard, Moderate plausibility. Applicable conditions: Paget's Disease, Neoplasm of Bone

Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma. These agents should only be used if the potential benefits are considered to outweigh the potential risks. Monitor these patients according to clinical guidelines. Patients with bone metastases or a history of skeletal malignancies should not be treated with these agents.

Major

Teriparatide (applies to Forteo) metabolic bone disorder

Major Potential Hazard, Moderate plausibility. Applicable conditions: Paget's Disease, Vitamin D Deficiency, Hungry Bone Syndrome, Osteodystrophy

The use of teriparatide in patients with metabolic bone disease, other than osteoporosis is not recommended by the manufacturer.

Moderate

Teriparatide (applies to Forteo) orthostatic hypotension

Moderate Potential Hazard, Moderate plausibility.

There have been reports of transient episodes of symptomatic orthostatic hypotension with the use of teriparatide in short-term clinical pharmacology studies. Caution is recommended when using this agent in patients at risk.

Moderate

Teriparatide (applies to Forteo) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

No pharmacokinetic differences were identified in patients with mild or moderate renal impairment after a single dose of teriparatide. In patients with severe renal impairment, the AUC and half-life of teriparatide were increased by 73% and 77%, respectively. Care should be exercised in patients undergoing dialysis for chronic renal failure as no studies have been performed in this patient population.

Moderate

Teriparatide (applies to Forteo) urolithiasis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Nephrolithiasis

Teriparatide should be used with caution in patients with active urolithiasis. If active or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered because of the potential to exacerbate urolithiasis in these patients.

Forteo (teriparatide) drug interactions

There are 6 drug interactions with Forteo (teriparatide)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.